Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 11/20 | 0.33 |
| ▸ | TET3 | O43151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.32 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.32 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 4/20 | 0.32 |
| ▸ | TEAD1 | P28347 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22970007 | 0.81 | CHRM1 (0.42) | JAK3BTK | |
| SCHEMBL22704583 | 0.81 | CHRM1 (0.42) | JAK3BTK | |
| SCHEMBL19909714 | 0.81 | CHRM1 (0.42) | JAK3BTK | |
| SCHEMBL23735765 | 0.79 | TET3 (0.34) | JAK3TET3KMT2AFBXL19CXXC5 | |
| SCHEMBL20326344 | 0.78 | JAK3 (0.33) | JAK3BTKTEAD1 | |
| SCHEMBL17624754 | 0.78 | CYP1A2 (0.48) | KMT2A | |
| SCHEMBL23444394 | 0.77 | JAK3 (0.40) | JAK3 | |
| SCHEMBL23446088 | 0.77 | JAK3 (0.40) | JAK3 | |
| SCHEMBL23323368 | 0.77 | JAK3 (0.35) | JAK3BTKTEAD1 | |
| SCHEMBL20314855 | 0.77 | BTK (0.34) | JAK3BTKTEAD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11045484-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-10988485-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20190345169-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2019-11-14 | — | — | US | disclosed |
| WO-2018119183-A2 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069657-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | JAK3 3267/4885TET3 4253/4885KMT2A 2151/4885 |
| US-11045484-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | JAK3 3209/4885TET3 4360/4885KMT2A 2069/4885 |
| US-11285135-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | JAK3 3508/4885TET3 4351/4885KMT2A 2726/4885 |
| US-20190345169-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | JAK3 3209/4885TET3 4360/4885KMT2A 2069/4885 |
| US-10988485-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | JAK3 3209/4885TET3 4360/4885KMT2A 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.